FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772652039> ?p ?o ?g. }

• W2772652039 endingPage "115545" @default.
• W2772652039 startingPage "115526" @default.
• W2772652039 abstract "// Fangfang Cai 1, * , Minghui Chen 1, 2, * , Daolong Zha 1 , Peng Zhang 2 , Xiangyu Zhang 1 , Nini Cao 1 , Jishuang Wang 2 , Yan He 2 , Xinxin Fan 2 , Wenjing Zhang 2 , Zhongping Fu 2 , Yueyang Lai 1, 3 , Zi-Chun Hua 1, 2 and Hongqin Zhuang 1 1 The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China 2 State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, China 3 Nanjing Industrial Innovation Center for Pharmaceutical Biotechnology, Nanjing, China * These authors have contributed equally to this work Correspondence to: Hongqin Zhuang, email: hqzhuang@nju.edu.cn Zi-Chun Hua, email: hzc1117@nju.edu.cn Keywords: celecoxib; curcumol; synergism; apoptosis; tumor metastasis Received: August 16, 2017      Accepted: December 05, 2017      Published: December 14, 2017 ABSTRACT Combinatorial therapies that target multiple signaling pathways may provide improved therapeutic responses over monotherapies. Celecoxib and curcumol are two highly hydrophobic drugs which show bioavailability problems due to their poor aqueous solubility. In the present study, we evaluated the effects of celecoxib and curcumol alone and in combination on cell proliferation, invasion, migration, cell cycle and apoptosis induction in non-small cell lung cancer (NSCLC) cells using in vitro and in vivo experiments. Our data showed that the sensitivity of a combined therapy using low concentration of celecoxib and curcumol was higher than that of celecoxib or curcumol alone. Suppression of NF-κB transcriptional activity, activation of caspase-9/caspase-3, cell cycle G1 arrest, and inhibition of survival MAPK and PI3K/AKT signaling pathway contributed to the synergistic effects of this combination therapy for induction of apoptosis. Additionally, either celecoxib alone or in combination with curcumol inhibited NSCLC cell migration and invasion by suppressing FAK and matrix metalloproteinase-9 activities. Furthermore, the combined treatment reduced tumor volume and weight in xenograft mouse model, and significantly decreased tumor metastasis nodules in lung tissues by tail vein injection. Our results confirm and provide mechanistic insights into the prominent anti-proliferative activities of celecoxib and/or curcumol on NSCLC cells, which provide a rationale for further detailed preclinical and potentially clinical studies of this combination for the therapy of lung cancer." @default.
• W2772652039 created "2017-12-22" @default.
• W2772652039 creator A5000269702 @default.
• W2772652039 creator A5025751114 @default.
• W2772652039 creator A5027961969 @default.
• W2772652039 creator A5036471899 @default.
• W2772652039 creator A5036921991 @default.
• W2772652039 creator A5038417134 @default.
• W2772652039 creator A5044306638 @default.
• W2772652039 creator A5046658556 @default.
• W2772652039 creator A5048719072 @default.
• W2772652039 creator A5055875257 @default.
• W2772652039 creator A5067761927 @default.
• W2772652039 creator A5082803092 @default.
• W2772652039 creator A5083633867 @default.
• W2772652039 creator A5087762063 @default.
• W2772652039 date "2017-12-14" @default.
• W2772652039 modified "2023-10-16" @default.
• W2772652039 title "Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer" @default.
• W2772652039 cites W1506887248 @default.
• W2772652039 cites W1575309121 @default.
• W2772652039 cites W1576582769 @default.
• W2772652039 cites W176308265 @default.
• W2772652039 cites W1963797741 @default.
• W2772652039 cites W1972727274 @default.
• W2772652039 cites W1978053309 @default.
• W2772652039 cites W1983787852 @default.
• W2772652039 cites W1984422911 @default.
• W2772652039 cites W1987987550 @default.
• W2772652039 cites W1988587254 @default.
• W2772652039 cites W1988996530 @default.
• W2772652039 cites W1993985442 @default.
• W2772652039 cites W1996785337 @default.
• W2772652039 cites W2002449811 @default.
• W2772652039 cites W2007456673 @default.
• W2772652039 cites W2015466129 @default.
• W2772652039 cites W2016066595 @default.
• W2772652039 cites W2016730049 @default.
• W2772652039 cites W2019393725 @default.
• W2772652039 cites W2039935312 @default.
• W2772652039 cites W2040470926 @default.
• W2772652039 cites W2044032261 @default.
• W2772652039 cites W2046293893 @default.
• W2772652039 cites W2050620617 @default.
• W2772652039 cites W2050693842 @default.
• W2772652039 cites W2055596716 @default.
• W2772652039 cites W2056259078 @default.
• W2772652039 cites W2058461395 @default.
• W2772652039 cites W2061994888 @default.
• W2772652039 cites W2067530950 @default.
• W2772652039 cites W2068140447 @default.
• W2772652039 cites W2068706791 @default.
• W2772652039 cites W2075082022 @default.
• W2772652039 cites W2078935333 @default.
• W2772652039 cites W2082812256 @default.
• W2772652039 cites W2083573754 @default.
• W2772652039 cites W2084965383 @default.
• W2772652039 cites W2088182309 @default.
• W2772652039 cites W2096047391 @default.
• W2772652039 cites W2099902447 @default.
• W2772652039 cites W2103562758 @default.
• W2772652039 cites W2104500108 @default.
• W2772652039 cites W2105372476 @default.
• W2772652039 cites W2108577553 @default.
• W2772652039 cites W2111406172 @default.
• W2772652039 cites W2120243715 @default.
• W2772652039 cites W2121619780 @default.
• W2772652039 cites W2121709505 @default.
• W2772652039 cites W2121887100 @default.
• W2772652039 cites W2128515425 @default.
• W2772652039 cites W2135086805 @default.
• W2772652039 cites W2135461728 @default.
• W2772652039 cites W2137138278 @default.
• W2772652039 cites W2138381757 @default.
• W2772652039 cites W2143160733 @default.
• W2772652039 cites W2144694529 @default.
• W2772652039 cites W2148122132 @default.
• W2772652039 cites W2166030420 @default.
• W2772652039 cites W2169556484 @default.
• W2772652039 cites W2169687232 @default.
• W2772652039 cites W2235523093 @default.
• W2772652039 cites W2272984102 @default.
• W2772652039 cites W2344189616 @default.
• W2772652039 cites W2917837889 @default.
• W2772652039 doi "https://doi.org/10.18632/oncotarget.23308" @default.
• W2772652039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5777791" @default.
• W2772652039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29383179" @default.
• W2772652039 hasPublicationYear "2017" @default.
• W2772652039 type Work @default.
• W2772652039 sameAs 2772652039 @default.
• W2772652039 citedByCount "26" @default.
• W2772652039 countsByYear W27726520392018 @default.
• W2772652039 countsByYear W27726520392019 @default.
• W2772652039 countsByYear W27726520392020 @default.
• W2772652039 countsByYear W27726520392021 @default.
• W2772652039 countsByYear W27726520392022 @default.
• W2772652039 countsByYear W27726520392023 @default.
• W2772652039 crossrefType "journal-article" @default.

• next